Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?
Puzzoni M, Silvestris N, Leone F, Giampieri R, Faloppi L, Demurtas L, Dell'Aquila E, Marino D, Brunetti O, Garattini SK, Ongaro E, Astara G, Orgiano L, Aprile G, Santini D, Scartozzi M. Puzzoni M, et al. Among authors: orgiano l. Target Oncol. 2016 Oct;11(5):593-603. doi: 10.1007/s11523-016-0437-6. Target Oncol. 2016. PMID: 27184491 Review.
HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors.
Sottile R, Pangigadde PN, Tan T, Anichini A, Sabbatino F, Trecroci F, Favoino E, Orgiano L, Roberts J, Ferrone S, Kärre K, Colucci F, Carbone E. Sottile R, et al. Among authors: orgiano l. Eur J Immunol. 2016 Feb;46(2):409-19. doi: 10.1002/eji.201445289. Epub 2015 Dec 20. Eur J Immunol. 2016. PMID: 26564811 Free PMC article.
Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors.
Stucci LS, D'Oronzo S, Tucci M, Macerollo A, Ribero S, Spagnolo F, Marra E, Picasso V, Orgiano L, Marconcini R, De Rosa F, Di Guardo L, Galli G, Gandini S, Palmirotta R, Palmieri G, Queirolo P, Silvestris F; Italian Melanoma Intergroup (IMI). Stucci LS, et al. Among authors: orgiano l. Cancer Treat Rev. 2018 Sep;69:21-28. doi: 10.1016/j.ctrv.2018.05.016. Epub 2018 May 31. Cancer Treat Rev. 2018. PMID: 29864718 Review.
Current status and perspectives in immunotherapy for metastatic melanoma.
Marconcini R, Spagnolo F, Stucci LS, Ribero S, Marra E, Rosa F, Picasso V, Di Guardo L, Cimminiello C, Cavalieri S, Orgiano L, Tanda E, Spano L, Falcone A, Queirolo P; Italian Melanoma Intergroup (IMI). Marconcini R, et al. Among authors: orgiano l. Oncotarget. 2018 Jan 3;9(15):12452-12470. doi: 10.18632/oncotarget.23746. eCollection 2018 Feb 23. Oncotarget. 2018. PMID: 29552325 Free PMC article. Review.
Effect of Age on Melanoma Risk, Prognosis and Treatment Response.
Ribero S, Stucci LS, Marra E, Marconcini R, Spagnolo F, Orgiano L, Picasso V, Queirolo P, Palmieri G, Quaglino P, Bataille V. Ribero S, et al. Among authors: orgiano l. Acta Derm Venereol. 2018 Jul 11;98(7):624-629. doi: 10.2340/00015555-2944. Acta Derm Venereol. 2018. PMID: 29648671 Free article. Review.
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M, Maurichi A, Orgiano L, Spadola G, Del Vecchio M, Danielli R, Calabrò L, Annesi D, Giannarelli D, Maccalli C, Fonsatti E, Parmiani G, Maio M. Di Giacomo AM, et al. Among authors: orgiano l. Ann Oncol. 2015 Apr;26(4):798-803. doi: 10.1093/annonc/mdu577. Epub 2014 Dec 23. Ann Oncol. 2015. PMID: 25538176 Free article. Clinical Trial.
11 results